Trial Purpose

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

View full trial information on Clinicaltrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT03742895

When speaking to your doctor, please have the trial identifier number available.

About The Trial

This is an open label study, which means both you and the study doctor will know what you are getting.  All patients who enroll in the trial will receive medication while on the study.*

100% will receive olaparib

*Patients must be centrally confirmed as HRR mutated, HRD positive, or BRCA mutated and meet all other I/E criteria to enroll in the trial.

Trial Phase Icon

Phase 2

Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.

Trial start Icon

Dates

  • Actual study start date December 12, 2018
  • Estimated primary completion date June 30, 2026
  • Estimated study completion date June 30, 2026

Eligibility

Conditions Icon

Conditions

Advanced Solid Neoplasms

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon

Sex

All

Trial locations

What Can You Do Next?

If you think this trial might be a fit and are interested in participating, take the next step to see if you are eligible.

Discuss Icon

Discuss With Your Doctor

Print this page or email it to your doctor to discuss at your next visit.

CLINICALTRIALS.GOV IDENTIFIER:

NCT03742895

When speaking to your doctor, please have the trial identifier number available.

Participating in a clinical trial is an important decision.

Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.